OBJECTIVES: The aim of this study was to evaluate the effects of alcohol septal ablation (ASA) on coronary blood flow in symptomatic hypertrophic obstructive cardiomyopathy (HOCM) using cardiac MR (CMR) coronary flow measurements. Background CMR flow mapping enables quantification of coronary blood flow in a noninvasive way. Both left ventricular outflow tract (LVOT) gradient reduction and myocardial scarring after ASA are expected to influence left anterior descending (LAD) coronary blood flow. METHODS: Cine, contrast-enhanced (CE) imaging and breath-hold CMR phase contrast velocity mapping were performed at baseline and 1 and 6 months after ASA in seven patients. Changes of coronary blood flow were related to left ventricular (LV) mass reduction, enzyme release, volume of ethanol administered, LVOT gradient reduction, and LV rate pressure product (LVRPP). RESULTS: A significant mass reduction was observed both in the target septal myocardium and in the total myocardium (both P < 0.01). Mean myocardial infarct size was 23 +/- 12 g (range 7.3-41.6 g). LVRPP decreased from 13,268 +/- 2,212 to 10,685 +/- 3,918 at 1 month (P = 0.05) and 9,483 +/- 2,496 mmHg beats/min at 6 months' follow-up (P < 0.01). LAD coronary blood flow decreased from 100 +/- 37 ml/min at baseline to 84 +/- 54 ml/min (P = 0.09) at 1 month and 67 +/- 33 ml/min at 6 months follow-up (P < 0.01). A significant correlation was found between the change in LVRPP and LAD coronary flow at 1 month follow-up (r = 0.83, P = 0.02). CE-infarct size tended to modulate the blood flow changes over time (P = 0.12); no correlation was observed between enzyme release, volume of ethanol or both septal and total mass reduction and coronary blood flow. CONCLUSION: The reduction in coronary blood flow is primarily associated with diminished LV loading conditions, whereas the induction of metabolically inactive myocardial scar tissue by ASA did not significantly influence the changes in coronary blood flow.
OBJECTIVES: The aim of this study was to evaluate the effects of alcohol septal ablation (ASA) on coronary blood flow in symptomatic hypertrophic obstructive cardiomyopathy (HOCM) using cardiac MR (CMR) coronary flow measurements. Background CMR flow mapping enables quantification of coronary blood flow in a noninvasive way. Both left ventricular outflow tract (LVOT) gradient reduction and myocardial scarring after ASA are expected to influence left anterior descending (LAD) coronary blood flow. METHODS:Cine, contrast-enhanced (CE) imaging and breath-hold CMR phase contrast velocity mapping were performed at baseline and 1 and 6 months after ASA in seven patients. Changes of coronary blood flow were related to left ventricular (LV) mass reduction, enzyme release, volume of ethanol administered, LVOT gradient reduction, and LV rate pressure product (LVRPP). RESULTS: A significant mass reduction was observed both in the target septal myocardium and in the total myocardium (both P < 0.01). Mean myocardial infarct size was 23 +/- 12 g (range 7.3-41.6 g). LVRPP decreased from 13,268 +/- 2,212 to 10,685 +/- 3,918 at 1 month (P = 0.05) and 9,483 +/- 2,496 mmHg beats/min at 6 months' follow-up (P < 0.01). LAD coronary blood flow decreased from 100 +/- 37 ml/min at baseline to 84 +/- 54 ml/min (P = 0.09) at 1 month and 67 +/- 33 ml/min at 6 months follow-up (P < 0.01). A significant correlation was found between the change in LVRPP and LAD coronary flow at 1 month follow-up (r = 0.83, P = 0.02). CE-infarct size tended to modulate the blood flow changes over time (P = 0.12); no correlation was observed between enzyme release, volume of ethanol or both septal and total mass reduction and coronary blood flow. CONCLUSION: The reduction in coronary blood flow is primarily associated with diminished LV loading conditions, whereas the induction of metabolically inactive myocardial scar tissue by ASA did not significantly influence the changes in coronary blood flow.
Authors: Willem G van Dockum; Aernout M Beek; Folkert J ten Cate; Jurrien M ten Berg; Olga Bondarenko; Marco J W Götte; Jos W R Twisk; Mark B M Hofman; Cees A Visser; Albert C van Rossum Journal: Circulation Date: 2005-05-02 Impact factor: 29.690
Authors: Manuela Jörg-Ciopor; Mehdi Namdar; Jurai Turina; Rolf Jenni; Jürg Schwitter; Marko Turina; Otto M Hess; Philipp A Kaufmann Journal: J Thorac Cardiovasc Surg Date: 2004-08 Impact factor: 5.209
Authors: Martin S Maron; Iacopo Olivotto; Sandro Betocchi; Susan A Casey; John R Lesser; Maria A Losi; Franco Cecchi; Barry J Maron Journal: N Engl J Med Date: 2003-01-23 Impact factor: 91.245
Authors: Osama I I Soliman; Marcel L Geleijnse; Michelle Michels; Pieter A Dijkmans; Attila Nemes; Bas M van Dalen; Wim B Vletter; Patrick W Serruys; Folkert J ten Cate Journal: Am J Cardiol Date: 2008-03-17 Impact factor: 2.778
Authors: Willem G van Dockum; Folkert J ten Cate; Jurrien M ten Berg; Aernout M Beek; Jos W R Twisk; Jeroen Vos; Mark B M Hofman; Cees A Visser; Albert C van Rossum Journal: J Am Coll Cardiol Date: 2004-01-07 Impact factor: 24.094
Authors: Paul Knaapen; Tjeerd Germans; Paolo G Camici; Ornella E Rimoldi; Folkert J ten Cate; Jurrien M ten Berg; Pieter A Dijkmans; Ronald Boellaard; Willem G van Dockum; Marco J W Götte; Jos W R Twisk; Albert C van Rossum; Adriaan A Lammertsma; Frans C Visser Journal: Am J Physiol Heart Circ Physiol Date: 2007-12-21 Impact factor: 4.733
Authors: Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Marios Matiakis; Hannes Melnyk; Sophie Mavrogeni; Dionyssios Leftheriotis; Boris Bigalke; Michel Noutsias Journal: Heart Fail Rev Date: 2019-05 Impact factor: 4.214
Authors: Bradley D Allen; Lubna Choudhury; Alex J Barker; Pim van Ooij; Jeremy D Collins; Robert O Bonow; James C Carr; Michael Markl Journal: Eur Heart J Cardiovasc Imaging Date: 2014-08-09 Impact factor: 6.875
Authors: Aya Kino; Aoife N Keeling; Cormac T Farrelly; John J Sheehan; Amir H Davarpanah; Peter J Weele; Sven Zuehldorff; James C Carr Journal: Int J Cardiovasc Imaging Date: 2010-05-26 Impact factor: 2.357